Document is current
Any future updates will be listed below
-
Authors
Graewert, Melissa A. https://orcid.org/0000-0001-7547-636X
Volkova, Maria https://orcid.org/0009-0000-3021-8586
Jonasson, Klara
Määttä, Juha A. E.
Gräwert, Tobias
Mamidi, Samara
Kulesskaya, Natalia https://orcid.org/0000-0001-5517-8525
Evenäs, Johan
Johnsson, Richard E.
Svergun, Dmitri
Bhattacharjee, Arnab https://orcid.org/0000-0002-9613-7911
Huttunen, Henri J. https://orcid.org/0000-0002-9867-4438
-
Funding
Funding for this research was provided by:
Internal research funding from Herantis Pharma Plc
EC | Horizon 2020 Framework Programme (871037)
- License Information
-
More Information
Article History
Received: 23 February 2024
Accepted: 5 September 2024
First Online: 18 September 2024
Competing interests
: N.K., A.B. and H.J.H. are employees and share or option right holders of Herantis Pharma Plc, who sponsored the study. M.V., K.J., S.M., J.E., and R.E.J. are employees of Red Glead Discovery AB. T.G. and D.S. are employees of BioSAXS GmbH. N.K., A.B. and H.J.H. are inventors in two international patent applications that are related to compounds that were developed partially based on the structural data shown in this paper. The applications are pending and have the application numbers: W.O. 2021/123047A1 and WO 2021/123050A1. All other authors declare no competing interests.
